John E De Leon

Title: John E De Leon: Innovator in Pharmaceutical Chemistry

Introduction

John E De Leon is a notable inventor based in North Bergen, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target melanin concentrating hormone-1 (MCH1) receptors. With a total of 2 patents, his work has implications for treating various medical conditions.

Latest Patents

One of his latest patents is titled "Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof." This invention focuses on compounds that act as selective antagonists for MCH1 receptors. It provides a pharmaceutical composition that includes a therapeutically effective amount of the compound along with a pharmaceutically acceptable carrier. The invention outlines methods for reducing body mass and treating subjects suffering from depression, anxiety, and urinary disorders.

Another significant patent is "Spirocyclic piperidines as MCH1 antagonists and uses thereof." Similar to his previous work, this invention also targets MCH1 receptors and offers a pharmaceutical composition with therapeutic applications. It includes methods for body mass reduction and treatment of depression, anxiety, and urinary disorders.

Career Highlights

Throughout his career, John E De Leon has worked with reputable companies such as H. Lundbeck A/S. His experience in the pharmaceutical industry has allowed him to develop innovative solutions that address critical health issues.

Collaborations

John has collaborated with notable professionals in his field, including Mohammad R Marzabadi and Yu Jiang. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

John E De Leon is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations in the treatment of various medical conditions. His contributions continue to impact the field positively.